Novel pharmaceutical formulations and their use in the treatment of periodontal disease

a technology of pharmaceutical formulations and periodontal disease, applied in the direction of pharmaceutical non-active ingredients, cyclic peptide ingredients, depsipeptide ingredients, etc., can solve the problems of no treatment that addresses, halt or reverse the tissue and bone destructive process, tooth loss, etc., and achieve the effect of improving long-term stability

Inactive Publication Date: 2020-03-19
PERIOC
View PDF0 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0021]According to one aspect of the invention, cyclophilin inhibitors may be used to treat periodontitis. According to another aspect, the cyclophilin inhibitors belong to the chemical classes of cyclosporins, sanglifehrins or cycloundecadepsipeptides. According to another aspect, the cyclophilin inhibitors may be applied locally into the gingival pocket. According to another aspect, the cyclophilin inhibitors may be applied as a micro- or nano-formulations. According to another aspect, the micro- or nano-formulation is mucoadhesive. According to another aspect, the micro- or nano-formulation allows the cyclophilin inhibitors to exhibit activity over a period of several days or weeks. The nano compositions can be formulated with non-ionic surfactants, for example TPGS and / or poloxamer 407. The composition may be applied as liquids, and which form gels in-situ. The in-situ forming system can be a suspension of cyclosporin nanoparticles which is applied into inflamed gingival pockets as a liquid, where it forms a gel upon exposure to physiological conditions. The in-situ forming systems allow the activity of the cyclosporin to be maintained over a period of several days or weeks. The long acting nature of the composition means that the treatment only needs to be applied once or twice in order to be effective.

Problems solved by technology

Periodontal diseases range from simple gum inflammation to serious disease that results in major damage to the soft tissue and bone that surround and support the teeth, ultimately resulting in tooth loss.
There is presently no treatment that addresses the events of the inflammatory response in a comprehensive way, notably its chronic manifestations, such that it would halt or reverse the tissue and bone destructive process.
However the topical treatments described herein will slow and / or stop the pathophysiology of chronic inflammation which must precede the physiological healing process, without causing the side effects induced by systemic treatment.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Novel pharmaceutical formulations and their use in the treatment of periodontal disease
  • Novel pharmaceutical formulations and their use in the treatment of periodontal disease
  • Novel pharmaceutical formulations and their use in the treatment of periodontal disease

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0253]To a 5% suspension of cyclosporin in glycerol were added under mechanical agitation (rotor-stator mixer, Ultra Turrax T25) 1% of TPGS, 0.01% chlorhexidine, 7% gelatin, and 10% hydroxypropyl cellulose. The resulting pre-dispersion was then homogenised using 3 cycles at 500 bar and 10 cycles at 1,500 bar in a Gaulin Micron Lab40 high pressure homogeniser at room temperature. Particle size analysis showed a D50% of 1.8 μM, a D75% of 4.6 μM and a D95% of 5.6 μM.

example 2

[0254]The same experimental protocol as in example 1 but using 20 high pressure homogenisation cycles gave cyclosporin nanoparticles with a D95% of 960 nM.

example 3

[0255]The experimental protocol of example 2 but substituting Polyoxamer 407 for TPGS and 20 high pressure homogenisation cycles gave cyclosporin nanoparticles with a D50% of 890 nM and a D95% of 1.7 μM.

[0256]General Nanomilling Procedure (Pilot Scale)

[0257]The indicated amount of purified water was weighed into a glass beaker of suitable size. Afterwards the listed amounts of surfactant and stabilising polymer were added under magnetic stirring until the components fully dissolved. The described amount of cyclosporin was slowly added under stirring to give an almost homogenous suspension. The suspension was transferred into the milling system (e.g. Netzsch, DeltaVita). The milling system has been previously loaded with milling beads with approx. 0.2 mm diameter. The milling is performed under controlled temperature conditions (<40° C.) over a suitable time (2-5 h) using an appropriate milling speed (2000-3000 rpm).

[0258]Characterisation

[0259]The isolated nano-suspensions have been ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
diameteraaaaaaaaaa
particle sizeaaaaaaaaaa
sizeaaaaaaaaaa
Login to View More

Abstract

The present invention relates to novel treatments of periodontal disease by administering a suitable formulation of a cyclophilin inhibitor. The present invention further relates to novel pharmaceutical compositions containing said cyclophilin inhibitor compounds.

Description

RELATED APPLICATION INFORMATION[0001]This application is a continuation of U.S. patent application Ser. No. 14 / 651,165, filed Jun. 10, 2015, which is a 371 of International Patent Application No.: PCT / GB2013 / 053283, filed Dec. 13, 2013, which claims priority from GB Patent Application No.: 1222455.6, filed Dec. 13, 2012. The entire contents of these applications are incorporated herein by reference.FIELD OF THE INVENTION[0002]The present invention relates to a new treatment of periodontal disease by administering a suitable topical formulation of a cyclophilin inhibitor into the gingival pockets. The method includes a new in-situ formulation and use of compounds. Further disclosed is a micro-formulation or nano-formulation of stabilised micro or nanoparticles. The novel nanoparticles may also be used in the treatment of periodontal disease. The formulation can be an in-situ forming system which is applied as a liquid, but forms a gel under physiological conditions.BACKGROUND OF THE ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(United States)
IPC IPC(8): A61K31/5025A61K9/10A61K47/34C07K7/64A61K9/00A61K9/14A61K38/13A61K38/15A61K47/10A61K47/22A61K31/155
CPCA61K31/5025A61K47/34A61K9/0063A61K31/155A61K9/145C07K7/645A61K47/10A61K47/22A61K9/10A61K38/15A61K38/13A61P1/02A61K2300/00A61K47/50A61K31/355A61K38/03
InventorKISSEL, THOMASMAK, CHING PONG
OwnerPERIOC